Pricing Log in Create free account
Saturday 17 October 2026 Export CTMX’s income statement to Excel — free account

CytomX Therapeutics, Inc.

CTMX Healthcare Biotechnology

CytomX Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $76.2 million, down 44.8% from fiscal 2024. In the quarter to June 2026, revenue fell 92.4%, EPS fell 7,400.0% and free cash flow fell 14.5%, each against the same quarter a year earlier.

2.27 0.14 −5.81%
Market cap
$525.1M
P/E
0.0×
Fwd P/E
−6.9×
Dividend yield
—
F-score
2/9
Altman Z
0.92
Beneish M
−1.09
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.69
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 1 — — — 4 — — 1 — — — —
Insider Ownership 19.37%

Capital & Financial Ratios $m

Market Cap 525.14
Revenue 18.30
Net Income (79.65)
Free Cash Flow (82.41)
Net Debt (331.20)
Current Ratio 9.36 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (6.86) (negative: loss-making)
P/S ratio 27.16 (above 10: high)
P/B ratio 1.65
Past 5Y EPS Growth —
This Y EPS Growth (154.28%) (below 0%: weak)
Next Y EPS Growth (20.00%) (below 0%: weak)
Next Y revenue growth (67.15%) (below 0%: weak)
Next 5Y EPS Growth (0.90%) (below 0%: weak)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 9.3×, against a ten-year median of 0.9×; over the ten years it ranged from −9.8× in 2016 to 36.4× in 2016.
P/S against its own 10 years 88.09%
10-year low 10-year high
P/B against its own 10 years 4.35%
10-year low 10-year high
EV/Sales against its own 10 years 71.00%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 175 101 137 331
Receivables 3 3 2 37
Inventory — — — —
Other — — — —
183 107 144 373
2023 2024 2025 Q'26
Payables 1 1 1 2
ST’ Debt — — — —
Other — — — —
156 86 47 40

Compound Annual Growth %

10y 5y 3y
Sales 25.74% (5.36%) 12.75%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (2.39%) 14.73% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 10 1 — — —
’25 51 19 6 1 76
’24 41 25 33 38 138
’23 23 25 26 27 101
’22 9 13 11 20 53
’21 16 16 18 (13) 37
’20 50 17 18 16 100
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (26) (18) — — —
’25 (21) (16) (16) (23) (76)
’24 (26) (20) (21) (20) (86)
’23 9 (25) (18) (22) (56)
’22 (41) (34) (34) (1) (111)
’21 (30) (28) (30) (31) (119)
’20 (50) 97 (25) (17) 5
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (26) (18) — — —
’25 (21) (16) (15) (23) (76)
’24 (26) (20) (21) (20) (87)
’23 9 (26) (18) (22) (57)
’22 (42) (35) (34) (2) (113)
’21 (31) (28) (30) (31) (121)
’20 (51) 97 (25) (18) 3
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.10) (0.09) — — —
’25 0.27 0.00 (0.09) (0.22) (0.15)
’24 0.17 (0.08) 0.07 0.22 0.38
’23 (0.05) (0.02) 0.04 0.01 (0.01)
’22 (0.37) (0.37) (0.35) (0.13) (1.51)
’21 (0.26) (0.30) (0.35) (0.91) (1.81)
’20 0.26 (0.34) (0.32) (0.31) (0.71)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 9.10 10.40 12.51 5.10 3.60 3.68 1.17 1.04 0.83 0.40

Analyst estimates 2026–2028

Powerpack
High 20.94 24.67 35.00 19.75 15.44 10.05 4.73 3.02 5.85 4.62
People
People Employees 80 93 139 160 146 178 118 122 121 69
Revenue/emp, $m 0.19 0.77 0.43 0.36 0.69 0.21 0.45 0.83 1.14 1.10
Income, $m
Income, $m Revenue 15 72 60 57 100 37 53 101 138 76
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
EBT (59) (44) (70) (103) (47) (116) (99) 3 32 (17)
EBT margin, % (391.67) (60.89) (118.15) (178.58) (46.63) (310.54) (186.82) 3.28 23.24 (22.48)
Net income (59) (43) (85) (102) (33) (116) (99) (1) 32 (17)
Depreciation 3 2 0 0 2 3 2 (5) (4) (1)
Per share, $
Per share, $ Revenue 0.42 1.93 1.43 1.27 2.17 0.58 0.81 1.37 1.64 0.55
Earnings (1.63) (1.16) (2.03) (2.26) (0.71) (1.81) (1.51) (0.01) 0.38 (0.15)
Cash flow (0.06) 4.58 (1.81) (3.10) 0.11 (1.86) (1.69) (0.76) (1.02) (0.55)
Capex (0.06) (0.04) (0.09) (0.08) (0.05) (0.03) (0.03) (0.01) 0.00 0.00
Free cash flow (0.11) 4.54 (1.90) (3.18) 0.06 (1.88) (1.71) (0.77) (1.02) (0.55)
Book value 2.17 1.88 3.14 1.13 1.08 (0.01) (1.30) (0.64) (0.01) 0.72
Shares, m 36 37 42 45 46 64 66 74 84 138
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.71 0.00
P/S 25.80 11.29 10.57 6.55 3.01 7.44 1.99 1.23 0.63 7.71
P/B 4.95 11.57 4.81 7.37 6.07 0.00 0.00 0.00 0.00 5.93
EV/Sales 13.70 6.07 3.24 1.45 (0.11) (0.64) (1.57) (0.45) (0.07) 5.97
EV/FCF (49.60) 2.57 (2.43) (0.58) (3.62) 0.20 0.74 0.80 0.11 (6.00)
Cash, $m
Cash, $m Operating cash flow (2) 170 (76) (140) 5 (119) (111) (56) (86) (76)
Capex (2) (2) (4) (3) (2) (2) (2) (1) 0 0
Free cash flow (4) 169 (79) (144) 3 (121) (113) (57) (87) (76)
Balance, $m
Balance, $m Working capital 152 327 348 218 223 232 84 27 22 97
Total debt — — — 3 3 4 4 5 — —
Net debt (182) (374) (436) (293) (313) (302) (190) (175) (101) (137)
Shareholders’ equity 78 70 131 51 50 0 (86) (47) 0 99
Returns, %
Returns, % ROA (29.72) (14.44) (19.80) (25.61) (9.40) (33.20) (33.09) (0.25) 19.77 (14.97)
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE (57.59) (58.09) (84.28) (112.35) (65.17) (469.64) 230.41 0.85 (133.06) (41.34)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

CytomX Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
VALN Valneva SE Sponsored ADR $560.4M 59.7× 19.4× −17.29% (below 0%: shrinking) n/m −56.05% (below 0%: shrinking) 15.29% (76.67%) Compare
STTK Shattuck Labs, Inc. $555.0M — (loss-making) — (loss-making) −10.31% (below 0%: shrinking) n/m +1.01% (above 0%: growing) 100.00% 0.00% Compare
VECT VectivBio Holding AG $545.5M — (loss-making) — (loss-making) — n/m — 91.93% 0.00% Compare
PBYI Puma Biotechnology, Inc. $543.0M 18.2× 24.2× +7.75% (above 0%: growing) +33.33% (above 0%: growing) −88.45% (below 0%: shrinking) 77.92% 13.42% Compare
DRUG Bright Minds Biosciences Inc. $534.7M — (loss-making) — — n/m −124.63% (below 0%: shrinking) 0.00% 0.00% Compare
FTH Faeth Therapeutics, Inc. $532.3M — (loss-making) — — n/m −174.24% (below 0%: shrinking) 0.00% 0.00% Compare
CTMX CytomX Therapeutics, Inc. $525.1M — (loss-making) — (loss-making) −92.40% (below 0%: shrinking) n/m −14.50% (below 0%: shrinking) 100.00% (1,677.08%)
CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR $524.8M — (loss-making) — (loss-making) −7.53% (below 0%: shrinking) n/m −31.52% (below 0%: shrinking) 0.00% 0.00% Compare
ACRS Aclaris Therapeutics, Inc. $513.7M — (loss-making) — (loss-making) −8.33% (below 0%: shrinking) n/m −98.77% (below 0%: shrinking) 10.80% (1,487.91%) Compare
Median of peers $538.9M — — −8.33% — −88.45% 13.05% 0.00%

All 614 Biotechnology stocks →

CytomX Therapeutics, Inc. (CTMX) key facts

  • Concern: CytomX Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $76.2 million, down 44.8% from fiscal 2024.
  • CytomX Therapeutics, Inc. (CTMX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, CTMX traded at $2.27, a market capitalization of $525.1 million.
  • Return on equity was −41.3% and debt-to-equity 0.00.
  • Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 0.92 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

CytomX Therapeutics, Inc. (CTMX) Latest News

13 May

Impact 5 · transcript
stockrow.com/CTMX · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com